source
- Biopharma optimism climbs after FDA commissioner Makary's exit, survey findsEndpoints Signal released its Q3 Biopharma Sentiment Index, showing the highest level of industry optimism in years, according to a survey of 569 insiders. The index’s regulatory score rose sharpl…
- Aspen Neuroscience and Bambusa Therapeutics each target $134 million IPOsAspen Neuroscience, a cell‑therapy company focused on Parkinson's disease, and Bambusa Therapeutics, a bispecific biotech, have filed SEC documents outlining plans for initial public offerings. Bo…